Validation of 30-gene risk model for ABC–DLBCL (activated B-cell–like diffuse large B-cell lymphoma) in population and clinical trial cohorts. The risk model was tested with survival restricted to 3 years. (A) The 30-gene signature distinguished high- and low-risk groups in the REMoDL-B clinical trial,⁷ (B) the R-CHOP arm of the Lymphoma/Leukemia Molecular Profiling Project (LLMPP) 2008 cohort,²⁸ and (C) the Haematological Malignancy Research Network (HMRN) population study:²⁹ red = high risk, blue = low risk. (D) Comparison of International Prognostic Index (IPI) scores and the risk groups defined using the linear predictor in the REMoDL-B cohort. (E) Comparison of genetic subcategories described by Lacy et al¹³ with risk groups defined using the linear predictor in the HMRN cohort. Of the 156 ABC cases in the HMRN data, the genomic subgroups were available for 98 cases.